ROS1 CD74-ROS1 G2032R

在存在CD74-ROS1重排的环唑天宁耐药非小细胞肺癌患者中观察到G2032R错义突变。独立的体外研究证实，这种突变仅在CD74-ROS1上对环唑天宁细胞有明显的抵抗力。多组研究表明，表达CD74-ROS1 G2032R的细胞系对体外单独给予卡博扎丁尼和福雷替尼均敏感。另外，一组患者在体外对阿来西尼、布赖加替尼、西替尼和azd3463产生了相对抗性。
The G2032R missense mutation has been observed in patients with crizotinib-resistant non-small cell lung cancer harboring CD74-ROS1 rearrangement. Independent in vitro studies have confirmed that this mutation confers marked resistance to crizotinib cells over CD74-ROS1 alone. Multiple groups have indicated CD74-ROS1 G2032R expressing cell lines are sensitive to both cabozantinib and foretinib individually administered in vitro. One group additionally showed this mutation conferred relative resistance to alectinib, brigatinib, ceritinib, and AZD3463 in vitro.